IN8bio, Inc. is a clinical-stage biopharmaceutical company headquartered in New York that focuses on developing gamma-delta T cell product candidates for oncology and autoimmune diseases. The company's pipeline includes several candidates at varying stages of development: INB-400, in Phase 2 trials for newly diagnosed glioblastoma; INB-200, a genetically modified autologous gamma-delta T cell product in Phase 1 for glioblastoma; and INB-100, an allogeneic candidate in Phase 1 for hematologic malignancies in patients undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta T cell engager targeting CD19 for both oncology and autoimmune indications; INB-300, utilizing its nsCAR-enabled DeltEx platform for liquid and solid tumors; and INB-500, derived from induced pluripotent stem cells for cancer treatment, which remains in preclinical development.
As a clinical-stage company with 17 full-time employees, IN8bio has not yet generated significant revenue. The company was incorporated in Delaware in 2016 and previously operated under the name Incysus Therapeutics before rebranding to IN8bio in August 2020. The company is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.57 | $-0.57 | +43.0% | |
| 2023 | $-1.00 | $-1.00 | +26.5% | |
| 2022 | $-1.36 | $-1.36 | — | |
| 2021 | — | — | — |